CTMX Valuation

CytomX Therapeutics Inc

Add to Watchlist

Advanced Chart

3.620

-0.57(-13.604%)1D

CTMX Relative Valuation

CTMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTMX is overvalued; if below, it's undervalued.

Historical Valuation

CytomX Therapeutics Inc (CTMX) is now in the Fair zone, suggesting that its current forward PS ratio of 3.62 is considered Fairly compared with the five-year average of 13.30. The fair price of CytomX Therapeutics Inc (CTMX) is between 2.98 to 6.75 according to relative valuation methord.

Relative Value

Fair Zone

2.98-6.75

Current Price：3.62

Fair

-13.79

Trailing

Forward

50.55

EV/EBITDA

CytomX Therapeutics Inc. (CTMX) has a current EV/EBITDA of 50.55. The 5-year average EV/EBITDA is -0.02. The thresholds are as follows: Strongly Undervalued below -23.54, Undervalued between -23.54 and -11.78, Fairly Valued between 11.74 and -11.78, Overvalued between 11.74 and 23.50, and Strongly Overvalued above 23.50. The current Forward EV/EBITDA of 50.55 falls within the Strongly Overvalued range.

-10.57

EV/EBIT

CytomX Therapeutics Inc. (CTMX) has a current EV/EBIT of -10.57. The 5-year average EV/EBIT is 0.09. The thresholds are as follows: Strongly Undervalued below -5.65, Undervalued between -5.65 and -2.78, Fairly Valued between 2.95 and -2.78, Overvalued between 2.95 and 5.82, and Strongly Overvalued above 5.82. The current Forward EV/EBIT of -10.57 falls within the Strongly Undervalued range.

3.62

CytomX Therapeutics Inc. (CTMX) has a current PS of 3.62. The 5-year average PS is 3.01. The thresholds are as follows: Strongly Undervalued below -1.70, Undervalued between -1.70 and 0.65, Fairly Valued between 5.37 and 0.65, Overvalued between 5.37 and 7.73, and Strongly Overvalued above 7.73. The current Forward PS of 3.62 falls within the Historic Trend Line -Fairly Valued range.

-34.63

P/OCF

CytomX Therapeutics Inc. (CTMX) has a current P/OCF of -34.63. The 5-year average P/OCF is -4.52. The thresholds are as follows: Strongly Undervalued below -17.17, Undervalued between -17.17 and -10.85, Fairly Valued between 1.81 and -10.85, Overvalued between 1.81 and 8.13, and Strongly Overvalued above 8.13. The current Forward P/OCF of -34.63 falls within the Strongly Undervalued range.

-63.65

P/FCF

CytomX Therapeutics Inc. (CTMX) has a current P/FCF of -63.65. The 5-year average P/FCF is -5.96. The thresholds are as follows: Strongly Undervalued below -24.57, Undervalued between -24.57 and -15.27, Fairly Valued between 3.35 and -15.27, Overvalued between 3.35 and 12.65, and Strongly Overvalued above 12.65. The current Forward P/FCF of -63.65 falls within the Strongly Undervalued range.

CytomX Therapeutics Inc (CTMX) has a current Price-to-Book (P/B) ratio of 4.98. Compared to its 3-year average P/B ratio of -6.47 , the current P/B ratio is approximately -176.95% higher. Relative to its 5-year average P/B ratio of -32.57, the current P/B ratio is about -115.28% higher. CytomX Therapeutics Inc (CTMX) has a Forward Free Cash Flow (FCF) yield of approximately -0.12%. Compared to its 3-year average FCF yield of -72.91%, the current FCF yield is approximately -99.84% lower. Relative to its 5-year average FCF yield of -64.68% , the current FCF yield is about -99.82% lower.

4.98

P/B

Median3y

-6.47

Median5y

-32.57

-0.12

FCF Yield

Median3y

-72.91

Median5y

-64.68

Competitors Valuation Multiple

The average P/S ratio for CTMX's competitors is 10.63, providing a benchmark for relative valuation. CytomX Therapeutics Inc Corp (CTMX) exhibits a P/S ratio of 3.62, which is -65.96% above the industry average. Given its robust revenue growth of -82.16%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CTMX.O

CytomX Therapeutics Inc

Akebia Therapeutics Inc

SIGA Technologies Inc

Corvus Pharmaceuticals Inc

7.60

567.58M

ZVRA.O

Zevra Therapeutics Inc

Rigel Pharmaceuticals Inc

35.19

25.59%

638.75M

Performance Decomposition

Market capitalization of CTMX increased by 241.51% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 0.39 to 7.40.

The secondary factor is the Revenue Growth, contributed -82.16%to the performance.

Overall, the performance of CTMX in the past 1 year is driven by P/E Change. Which is more unsustainable.

-82.16%

33.43M → 5.96M

Revenue Growth

-1490.56%

17.16 → -238.62

Margin Expansion

1814.23%

0.39 → 7.40

P/E Change

241.51%